Cetrorelix pamoate intermittent IM [intramuscular] dosage regimens in patients with symptomatic BPH: a 1 year placebo-controlled efficacy study and long-term safety assessment.

Trial Profile

Cetrorelix pamoate intermittent IM [intramuscular] dosage regimens in patients with symptomatic BPH: a 1 year placebo-controlled efficacy study and long-term safety assessment.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Cetrorelix (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Registrational; Therapeutic Use
  • Sponsors AEterna Zentaris Inc
  • Most Recent Events

    • 18 Jan 2011 Additional trial locations (Bulgaria, Germany) identified as reported by ClinicalTrials.gov.
    • 29 Dec 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Aug 2009 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top